YOUR SEARCH FOR Text 27 RESULTS
11 of Total
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… third quarter (Q3'23) (+12% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $636 … range of $2.59 - $2.62 billion – Opzelura ® (ruxolitinib) cream net product revenues of $92 …
12 of Total
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… in Q3 2021 (+25% vs. Q3 2020); Jakafi ® (ruxolitinib) revenues of $547 million in Q3 2021 … regulatory approvals including Opzelura TM (ruxolitinib) cream in the U.S. for the treatment …
13 of Total
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… the third quarter (Q3'24) (+24% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $741 … range of $2,740 - $2,770 million Opzelura ® (ruxolitinib) cream net product revenues of $139 …
14 of Total
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… the first quarter (Q1'24) (+9% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $572 … of $2,690 - $2,750 million – Opzelura ® (ruxolitinib) net product revenues of $86 million …
15 of Total
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… second quarter (Q2'24) (+9% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $706 … range of $2,710 - $2,750 million – Opzelura ® (ruxolitinib) net product revenues of $122 …
16 of Total
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance
… (+15% Y/Y) for the full year 2024 – Jakafi ® (ruxolitinib) net revenues of $773 million (+11% … million for the full year 2025 – Opzelura ® (ruxolitinib) cream net revenues of $162 million …
17 of Total
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… $922 million in Q1'25 (+26%Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $709 … from $2,925 - $2,975 million – Opzelura ® (ruxolitinib) cream net product revenues of $119 …
18 of Total
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… $1,059 million in Q2'25 (+17%Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $764 … $2,950 - $3,000 million ] – Opzelura ® (ruxolitinib) cream net product revenues of $164 …
19 of Total
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates | Incyte
… compared to the third quarter of 2024 Jakafi ® (ruxolitinib) net product revenue of $791 million … compared to the same period in 2024 Opzelura ® (ruxolitinib) cream net product revenue of $188 …
20 of Total
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results | Incyte
… was primarily related to demand for Jakafi ® (ruxolitinib) and Opzelura ® (ruxolitinib) cream, as well as the strong uptake …